ADNI-related initiatives in Europe. E-ADNI neugrid/outgrid EADC/ADNI harmonization of hippo manual segmentation
|
|
|
- Marylou Bradford
- 6 years ago
- Views:
Transcription
1 ADNI-related initiatives in Europe E-ADNI neugrid/outgrid EADC/ADNI harmonization of hippo manual segmentation
2 Pharma-Cog AIM: To develop new markers homologous in animal and humans sensitive to symptomatic effects and disease modification Development of markers in ANIMALS Development of markers in HUMANS
3 neugrid and outgrid: THE CONCEPT
4 FP7 outgrid A Worldwide e-infrastructure for Computational Neuroscientists Access to large image datasets Image analysis algorithms Grid-based high performance computing Image analysis algorithms Grid-based high performance computing Home to world largest image dataset on Alzheimer s Image analysis algorithms Friendly Pipeline Interface Centralized high performance computing
5 neugrid/outgrid Agreement w/ A Toga and A Evans to progress towards integration of the three infrastructures. A proof-of-concept challenge will be done by the end of 2010 (any source-any sink)
6 CSF total tau Alzheimer THE CONCEPT Hippocampal volume as a diagnostic marker Structure: MR hippo volumetry Function: FDG PET Amyloid deposits: PET Biochemistry: CSF tau/abeta Normal CSF Abeta42 Dubois, Feldman et al., Lancet Neurol 2007
7 THE CONCEPT The effect of segmentation protocols on hippocampal volume Ref. Med border Lat border Watson et al. Zipursk y et al. Mesial edge of temporal lobe Regional outline at choroidal fissure Temp horn of lat ventr Not mentioned Inf border Incl subicular complex & uncal cleft w/ border separating subicular complex from parahippo gyrus The interface of hippocampal tissue and parahippocampal gyrus white matter Norm. hippo vol (cm 3 ) Left Right Geuze et al., Mol Psychiatry 2005;10:147-59
8 THE CONCEPT Hippocampal volume as an outcome measure in trials of disease modifiers Drug Study Effect Segment. method Ref Tramiprosate Alphase 68% (100 mg) 120% (150 mg) Atorvastatin ADCLT CHV* mm³ vs p>.05 Not mentioned Manual protocol Insausti et al., 1998 AJNR; Machulda et al., 2001, Neuroimage Gauthier et al., JNHA 2009 Sparks et.a,l CCJM,2008 LEADe significant at p<.05 MIDAS (semiautomated) Jones et al., Alz&Dem 2008 Feldman et al., Neurology 2010 AN1792 CHV* % vs p = Manual protocol Watson et al., 1992, Neurology Fox N et al., Neurology, 2005 Xaliproden Sanofi- Aventis Trials significant atrophy Not mentioned From Vellas B et al. (Review), Lancet Neurol.,2008 Donepezil CHV* % vs p= 0.07 ε4 carriers only Manual protocol Jack et al., 1989;Radiology Jack et al., 2004; Neurology Jack CR et al., Neurobiol. Aging, 2008
9 BACKGROUND Hippocampal volume (manual segmentation) gold standard for automated segmentation algorithm Morey et al., NeuroImage 2009
10 AIMS To Harmonize Available Protocols for Manual Hippocampal Segmentation To Test the Validity of the Harmonized Protocol
11 AUTHORS OF HIPPO PROTOCOLS Bartzokis G, et al. Psychiatry Res 1998;82:11-24 Convit A, et al. Neurobiol Aging 1997;18:131-8 Haller JW, et al. Radiology 1997;202: Jack CR Jr. Epilepsia 1994;35 - Suppl 6:S21-9 Killiany RJ, et al. Arch Neurol 1993;50: Lehéricy S, et al. Am J Neuroradiol 1994;15: Malykhin NV, et al. Psychiatry Res 2007;155: Pantel J, et al. Hippocampus 2000;10:752-8 Pruessner JC, et al. Cereb Cortex 2000;10: Soininen HS, et al. Neurology 1994;44:1660-8
12 THE WORKGROUP EADC F Barkhof/P Scheltens B Dubois/S Leherici N Fox/J Barnes GB Frisoni H Hampel/J Pantel A Simmons H Soininen S Teipel LO Wahlund Amsterdam Paris London Brescia Frankfurt London Kuopio Rostock Stockholm
13 THE WORKGROUP ADNI CR Jack Jr Rochester, MN G Barzokis UCLA, CA D Bennet Chicago, IL J Csernansky NorthW U, WA C DeCarli UC Davis, CA M De Leon New York, NY J Kaye Portland, OR R Killiany Boston USM, MA PM Thompson LoNI, UCLA, CA M Weiner/S Mueller UCSF/VAMC
14 THE WORKGROUP other relevant hippo experts R Camicioli J O Brien J Pruessner Univ Alberta, Canada NewCastle, UK McGill, QC, Canada
15 THE WORKGROUP Boards EADC-ADNI P.I.s B Vellas B Winblad M Weiner Toulouse, France Stockholm, Sweden UCSF, US Population-based studies M Breteler / T Den Heijer P Sachdev/ JJ Maller L Launer W Jagust Rotterdam Scan Study PATH through life NIA Bethesda Berkeley
16 THE WORKGROUP Boards Statistical Board S Duchesne L Collins P Pasqualetti Clinical Advisor PJ Visser Netherlands Laval Univ, Canada MNI, McGill, Montreal AFaR, Rome Maastricht, The Dissemination/Education G Waldemar Copenhagen, Denmark
17 THE WORKGROUP Personnel in Brescia Marina Boccardi Rossana Ganzola Enrica Cavedo Michela Pievani Anna Caroli Alberto Redolfi psychologist, PhD psychologist psychologist mathematician mathematician bioinformaticist
18 PRELIMINARY RESULTS
19 EADC-ADNI Harmonization of Hippocampal Volumetry A meeting has been hold in Toronto yesterday (co-chair Cliff jack) to update. Oral communication will be given at Imaging preconference at ICAD Featured Research Symposium of the AIC will take place at ICAD
20
HHS Public Access Author manuscript Alzheimers Dement. Author manuscript; available in PMC 2016 February 01.
HHS Public Access Author manuscript Published in final edited form as: Alzheimers Dement. 2015 February ; 11(2): 126 138. doi:10.1016/j.jalz.2014.02.009. Delphi definition of the EADC-ADNI Harmonized Protocol
Marina Boccardi Thomson Reuter Researcher ID: B ORCID ID: Update: May 2014
Marina Boccardi Thomson Reuter Researcher ID: B-2733-2010 ORCID ID: 0000-0001-6744-8246 Update: May 2014 Education: Degree in Experimental Psychology Psychobiology, 110/110 cum laude, University of Padua-
Curriculum Vitae. Personal information. Work experience. First name / Surname Martina BOCCHETTA
Curriculum Vitae Personal information First name / Surname Martina BOCCHETTA E-mail mbocchetta@fatebenefratelli.it Nationality Italian Place and Date of birth Bergamo (Italy), May, 9 th 1986 Gender female
MRI Hippocampal Volume for Enrichment
MRI Hippocampal Volume for Enrichment Derek Hill 1,2 & Jerry Novak 3, Pat Cole 4, Diane Stephenson 5 1. IXICO plc 2. UCL, London, UK 3. Johnson and Johnson 4. Takeda 5. CAMD, Critical Path Institute 1
Changing diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
SUPPLEMENTARY INFORMATION In format provided by Frank et al. (JULY 2010)
Table 1 Imaging bios for Alzheimer s Visual rating High correlation with Multicenter studies have Accuracy for longitudinal hippocampus volume (R 2 been performed, but changes only at chance about 0.9,
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
How can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
Neuro-Imaging in dementia: using MRI in routine work-up Prof. Philip Scheltens
Neuro-Imaging in dementia: Philip Scheltens Alzheimer Center VU University Medical Center Amsterdam The Netherlands 1 Outline of talk Current guidelines Imaging used to exclude disease Specific patterns
Harvard Medical School Curriculum Vitae
Harvard Medical School Curriculum Vitae Date Prepared: August 9, 2017 Name: Office Address: Corinna Bauer Department of Ophthalmology Massachusetts Eye & Ear Infirmary 20 Staniford Street 2W-257 Boston,
Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study
630 Department of linical Neuroscience, Occupational Therapy and Elderly are Research, Karolinska Institute, Huddinge University Hospital L-O Wahlund P Julin P Scheltens Department of Statistics, Stockholm
ORIGINAL CONTRIBUTION. Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease
ORIGINAL CONTRIBUTION Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease Basil H. Ridha, MRCP; Josephine Barnes, MA, PhD; Laura A. van de Pol, MD; Jonathan M. Schott, MD,
Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias
15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease
ADNI PET CORE. Boston April Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price
ADNI PET CORE Boston April 27 Bill Jagust, Suzanne Baker, Bob Koeppe, Eric Reiman, Kewei Chen, Chet Mathis, Julie Price ADNI Florbetapir scan counts Number of Florbetapir scans N SMC EMCI LMCI AD Total
WWADNI MRI Core Boston July 2013
WWADNI MRI Core Boston July 2013 Bret Borowski - Mayo Matt Bernstein - Mayo Jeff Gunter Mayo Clifford Jack - Mayo David Jones - Mayo Kejal Kantarci - Mayo Denise Reyes Mayo Matt Senjem Mayo Prashanthi
Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.
Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D. Professor of Clinical Neurosciences, University of Geneva Médecin Responsable, Memory Clinic, Hôpitaux Universitaires
Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer s disease
J Neurol Neurosurg Psychiatry 2001;71:441 447 441 Magnetic Resonance Unit, Veterans AVairs Medical Center (114M), University of California, San Francisco 4150, Clement Street, San Francisco, CA 94121,
TOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION. Paul S. Aisen, MD Department of Neurosciences University of California, San Diego
TOWARD EFFECTIVE ALZHEIMER S THERAPY: PROGRESS AND COLLABORATION Paul S. Aisen, MD Department of Neurosciences University of California, San Diego Brief History of AD Therapeutics 1906: Dr. Alois Alzheimer
Curriculum Vitae. Education 2007 B.Mus.A. Piano Performance University of Western Ontario
Curriculum Vitae Date Prepared: October 4, 2018 Name:, Ph.D. Education 2007 B.Mus.A. Piano Performance University of Western Ontario 2007 B.Sc. Physiology and Psychology University of Western Ontario 2008
Fully-automated volumetric MRI with normative ranges: Translation to clinical practice
Behavioural Neurology 21 (2009) 21 28 21 DOI 10.3233/BEN-2009-0226 IOS Press Fully-automated volumetric MRI with normative ranges: Translation to clinical practice J.B. Brewer Department of Radiology and
Alzheimer disease (AD) is the most common form of dementia
ORIGINAL RESEARCH F.L. Giesel H.K. Hahn P.A. Thomann E. Widjaja E. Wignall H. von Tengg-Kobligk J. Pantel P.D. Griffiths H.O. Peitgen J. Schroder M. Essig Temporal Horn Index and Volume of Medial Temporal
NEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.
NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish
8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
Journal of Internal Medicine 2004; 256: 240 246 KEY SYMPOSIUM Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
Multi-template approaches for segmenting the hippocampus: the case of the SACHA software
Multi-template approaches for segmenting the hippocampus: the case of the SACHA software Ludovic Fillon, Olivier Colliot, Dominique Hasboun, Bruno Dubois, Didier Dormont, Louis Lemieux, Marie Chupin To
Tammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
Visual Rating Scale Reference Material. Lorna Harper Dementia Research Centre University College London
Visual Rating Scale Reference Material Lorna Harper Dementia Research Centre University College London Background The reference materials included in this document were compiled and used in relation to
G B Frisoni, P h Scheltens, S Galluzzi, F M Nobili, N C Fox, P H Robert, H Soininen, L-O Wahlund, G Waldemar, E Salmon ...
REVIEW Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC G B Frisoni, P h Scheltens, S Galluzzi,
Normal Aging of the brain
Normal Aging of the brain Marco Essig MD Prof. of Radiology, University of Heidelberg Department of Radiology, German Cancer Research Center Im Neuenheimer Feld 280, D-69120 Heidelberg Germany Contact:
The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
Neuroimaging strutturale nello studio delle malattie psichiatriche Marina Boccardi LENITEM (Laboratory of Epidemiology, Neuroimaging & Telemedicine)
SIN Corso di Aggiornamento in Neuroimmagini Brescia, 26 Marzo 2009 Neuroimaging strutturale nello studio delle malattie psichiatriche Marina Boccardi LENITEM (Laboratory of Epidemiology, Neuroimaging &
Automatic pathology classification using a single feature machine learning - support vector machines
Automatic pathology classification using a single feature machine learning - support vector machines Fernando Yepes-Calderon b,c, Fabian Pedregosa e, Bertrand Thirion e, Yalin Wang d,* and Natasha Leporé
Neuroimaging has traditionnally
Imaging and Alzheimer s Disease: A Review Neuroimaging in Alzheimer s disease (AD) has moved beyond the stage where it was used purely to exclude other disease processes. Structural brain magnetic resonance
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence
16th Annual MCI Symposium January 20, 2018 Miami, FL Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant,
Brain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
The most common cause of dementia is Alzheimer disease.
ORIGINAL RESEARCH A.J. Bastos-Leite J.H. van Waesberghe A.L. Oen W.M. van der Flier P. Scheltens F. Barkhof Hippocampal Sulcus Width and Cavities: Comparison Between Patients with Alzheimer Disease and
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
AnalyzePro HIPPOCAMPAL VOLUME ASSESSMENT
AnalyzePro HIPPOCAMPAL VOLUME ASSESSMENT HIPPOCAMPAL VOLUME ASSESSMENT GUIDE Introduction page 1 Loading Data page 4 Preprocessing Steps page 5 Manual AC-PC Alignment of Brain Data page 6 Cropping and
Alzheimer disease is the most common cause of dementia in
ORIGINAL RESEARCH BRAIN Automated Segmentation of Hippocampal Subfields in Drug-Naïve Patients with Alzheimer Disease H.K. Lim, S.C. Hong, W.S. Jung, K.J. Ahn, W.Y. Won, C. Hahn, I.S. Kim, and C.U. Lee
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development Wm Z Potter, MD, PhD Sr. Advisor, NIMH IOM, Nov 15, 2014 Disclosures Former employee of Lilly
Medial temporal lobe atrophy ratings in a large 75-year-old population-based cohort: gender-corrected and education-corrected normative data
Eur Radiol (2018) 28:1739 1747 https://doi.org/10.1007/s00330-017-5103-6 NEURO Medial temporal lobe atrophy ratings in a large 75-year-old population-based cohort: gender-corrected and education-corrected
First Scientific Symposium Translational Research in Alzheimer. Paris - September 18, 2009 Collège de France
First Scientific Symposium Translational Research in Alzheimer Paris - September 18, 2009 Collège de France 8h30 Welcome coffee 9h-9h30 Opening remarks - Philippe Lagayette, President of French National
Imaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
General introduction
1 General introduction 10 Chapter 1 General Introduction Dementia Dementia is defined as an acquired impairment of cognitive function in at least two domains, including memory, which interferes with normal
Arg-ADNI. Gustavo E. Sevlever, Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, Ricardo F. Allegri(*) and Arg-ADNI group.
Arg-ADNI Gustavo E. Sevlever, Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, Ricardo F. Allegri(*) and Arg-ADNI group. Memory and Aging Center Institute for Neurological Research (FLENI) Buenos
review of existing studies on ASL in dementia Marion Smits, MD PhD
review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam
Advances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017
Advances in Alzheimer s diagnosis; implications for clinical practice Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Grand Challenge Alzheimer s disease 47 million worldwide
Creating three dimensional models of Alzheimer s disease
Marks et al. 3D Printing in Medicine (2017) 3:13 DOI 10.1186/s41205-017-0020-5 RESEARCH Open Access Creating three dimensional models of Alzheimer s disease Matthew Marks 2, Amy Alexander 2, Joseph Matsumoto
HIPPOCAMPAL VOLUME ASSESSMENT. Using Analyze
HIPPOCAMPAL VOLUME ASSESSMENT Using Analyze 2 Table Of Contents 1. Introduction page 3 2. Preprocessing Steps page 6 I. Manual AC-PC Alignment of Brain Data page 7 II. Upsampling and Cropping for Improved
Neuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
Dementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
Issues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
T1-weighted Axial Visual Rating Scale for an Assessment of Medial Temporal Atrophy in Alzheimer s Disease
Journal of Alzheimer s Disease 41 (2014) 169 178 DOI 10.3233/JAD-132333 IOS Press 169 T1-weighted Axial Visual Rating Scale for an Assessment of Medial Temporal Atrophy in Alzheimer s Disease Geon Ha Kim
PDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a postprint version which may differ from the publisher's version. For additional information about this
Mild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
Neuroimaging in Dementia
Outline Neuroimaging in Dementia Frederik Barkhof Dept of Radiology & Nuclear Medicine VUMC Amsterdam NL Institutes of Neurology & Biomedical Engineering UCL London UK f.barkhof@vumc.nl; f.barkhof@ucl.ac.uk
Outline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
The availability of in vivo biomarkers of Alzheimer
Downloaded from jnm.snmjournals.org by on November 16, 20. For personal use only. Journal of Nuclear Medicine, published on February 17, 2012 as doi:10.2967/jnumed.111.094946 Summary Metrics to Assess
NeuroReport 2011, 22: a Laboratory of Neuro Imaging, Department of Neurology, UCLA School of. Received 9 March 2011 accepted 13 March 2011
Ageing 391 Homocysteine effects on brain volumes mapped in 732 elderly individuals Priya Rajagopalan a, Xue Hua a, Arthur W. Toga a, Clifford R. Jack Jr b, Michael W. Weiner c,d and Paul M. Thompson a
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative Leslie M Shaw Perelman School of Medicine, University of Pennsylvania
DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
Disclosure Statement
Recommendations on MCI from the Third and Fourth Canadian Consensus Conferences on Diagnosis and Therapy of Dementia/ Quatrieme Conférence Canadienne Consensuelle sur la Démence 2012. Dr. Howard Chertkow
Molecular Imaging Heterogeneity of Clinically Defined AD
Molecular Imaging Heterogeneity of Clinically Defined AD Gil Rabinovici, M.D. Edward Fein & Pearl Landrith Endowed Professor UCSF Memory & Aging Center 2017 Spring ADC Meeting Boston, MA April 22, 2017
Morphometric MRI Analysis of the Parahippocampal Region in Temporal Lobe Epilepsy
Morphometric MRI Analysis of the Parahippocampal Region in Temporal Lobe Epilepsy NEDA BERNASCONI, a ANDREA BERNASCONI, ZOGRAFOS CARAMANOS, FREDERICK ANDERMANN, FRANÇOIS DUBEAU, AND DOUGLAS L. ARNOLD Department
North Savo District Hospital, Iisalmi (Finland) Resident in Neurology, Dept. of Neurology. Kuopio University Hospital, Kuopio (Finland)
Curriculum vitae PERSONAL INFORMATION Maija Pihlajamaki WORK EXPERIENCE August 1997 January 1998 Intern, Internal Medicine North Savo District Hospital, Iisalmi (Finland) February 1998 October 2004 Research
Characterizing Anatomical Variability And Alzheimer s Disease Related Cortical Thinning in the Medial Temporal Lobe
Characterizing Anatomical Variability And Alzheimer s Disease Related Cortical Thinning in the Medial Temporal Lobe Long Xie, Laura Wisse, Sandhitsu Das, Ranjit Ittyerah, Jiancong Wang, David Wolk, Paul
Assessing Brain Volumes Using MorphoBox Prototype
MAGNETOM Flash (68) 2/207 33 Assessing Brain Volumes Using MorphoBox Prototype Alexis Roche,2,3 ; Bénédicte Maréchal,2,3 ; Tobias Kober,2,3 ; Gunnar Krueger 4 ; Patric Hagmann ; Philippe Maeder ; Reto
Stephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
NIH Public Access Author Manuscript Neuroimaging Clin N Am. Author manuscript; available in PMC 2008 May 12.
NIH Public Access Author Manuscript Published in final edited form as: Neuroimaging Clin N Am. 2005 November ; 15(4): 869 xii. The Alzheimer s Disease Neuroimaging Initiative Susanne G. Mueller, MD a,
Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and Molecular Imaging 2017 Annual Meeting
FOR IMMEDIATE RELEASE Media Contacts: Nicole Fletcher Piramal Imaging nicole.fletcher@piramal.com (857) 202-1122 Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
Frisoni 1. LENITEM (Laboratory of Epidemiology, Neuroimaging and Telemedicine) IRCCS S. Giovanni di Dio Fatebenefratelli Brescia, Italy;
Frisoni 1 Imaging Markers for Alzheimer s Disease: Which versus How GB. Frisoni 1*, MD; M. Bocchetta 1, MS; G. Chételat 2,3,4,5, PhD; GD. Rabinovici 6, MD; MJ. de Leon 7, MD, PhD; J. Kaye 8, MD; EM. Reiman
Regulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
Physiological Markers of Pharmacoresistant Epilepsy December 2, 2011
Physiological Markers of Pharmacoresistant Epilepsy December 2, 2011 Jerome Engel, Jr., MD, PhD Director of the Seizure Disorder Center The Jonathan Sinay Distinguished Professor of Neurology, Neurobiology,
European Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
NIH Public Access Author Manuscript Neuroreport. Author manuscript; available in PMC 2012 June 11.
NIH Public Access Author Manuscript Published in final edited form as: Neuroreport. 2011 June 11; 22(8): 391 395. doi:10.1097/wnr.0b013e328346bf85. Homocysteine effects on brain volumes mapped in 732 elderly
HOMOTAURINE INVESTIGATIONAL SUMMARY
HOMOTAURINE INVESTIGATIONAL SUMMARY Amyloid Precursor Protein (brain) Amyloid Aß Amyloid fibril Amyloid plaque action mechanism Aisen PS. Presented at: 9th International Geneva Springfield Symposium on
PRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans
PRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans Inclusion Criteria Clinical syndrome Patients must have clinical evidence
Use of Structural Magnetic Resonance Imaging to Predict Who Will Get Alzheimer s Disease
Use of Structural Magnetic Resonance Imaging to Predict Who Will Get Alzheimer s Disease Ronald J. Killiany, PhD,* Teresa Gomez-Isla, MD, PhD, Mark Moss, PhD,* Ron Kikinis, MD, Tamas Sandor, PhD, Ferenc
Positioning. > MEMENTO is a large observational study enrolling patients at an. Data first availability for project analyses
: determinants and Evolution of AlzheiMer s disease and related disorders ITMO Santé publique OVERVIEW AT A GLANCE Bordeaux Geneviève Chêne, MD, PhD Professor of Biostatistics and Public Health, Bordeaux
MR Differential Diagnosis of Normal-Pressure Hydrocephalus and Alzheimer Disease: Significance of Perihippocampal Fissures
AJNR Am J Neuroradiol 19:813 819, May 1998 MR Differential Diagnosis of Normal-Pressure Hydrocephalus and Alzheimer Disease: Significance of Perihippocampal Fissures Andrei I. Holodny, Robert Waxman, Ajax
Mild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
Automatic thalamus and hippocampus segmentation from MP2RAGE: comparison of publicly available methods and implications for DTI quantification
Automatic thalamus and hippocampus segmentation from MP2RAGE: comparison of publicly available methods and implications for DTI quantification Erhard Næss-Schmidt, Anna Tietze, Jakob Udby Blicher, Mikkel
Original Article An MRI study of age-related changes in the dimensions related temporal lobe
Int J Clin Exp Med 2014;7(3):515-522 www.ijcem.com /ISSN:1940-5901/IJCEM1401017 Original Article An MRI study of age-related changes in the dimensions related temporal lobe Ismail Salk 1, Mehmet Haydar
Cognitive ageing and dementia: The Whitehall II Study
Cognitive ageing and dementia: The Whitehall II Study Archana SINGH-MANOUX NIH: R01AG013196; R01AG034454; R01AG056477 MRC: K013351, MR/R024227 BHF: RG/13/2/30098 H2020: #643576 #633666 Outline Lifecourse
CONSENSUS STATEMENT ON DEMENTIA EDUCATION AND TRAINING IN EUROPE
CONSENSUS STATEMENT ON DEMENTIA EDUCATION AND TRAINING IN EUROPE M. TSOLAKI 1, V. PAPALIAGKAS 2, G. ANOGIANAKIS 2, R. BERNABEI 3, M. EMRE 4, L. FROLICH 5, P.J. VISSER 6, J.-P. MICHEL 7, T. PIRTTILA 8,
A Harmonized Segmentation Protocol for Hippocampal and Parahippocampal Subregions: Why Do We Need One and What Are the Key Goals?
HIPPOCAMPUS 27:3 11 (2017) COMMENTARY A Harmonized Segmentation Protocol for Hippocampal and Parahippocampal Subregions: Why Do We Need One and What Are the Key Goals? Laura E.M. Wisse, 1 * Ana M. Daugherty,
FINAL AGENDA Administrators Meeting
Administrators informal social hour (Food and drink on your own) 6 8pm Thursday, April 19 Hilton Checkers Los Angeles 535 S Grand Ave 90071 FINAL AGENDA Administrators Meeting Friday, April 20, 2018 1
Submitted to NeuroImage: December 3, 2007 Revised Version submitted: February 9, nd Revision submitted: May 26, 2008
Validation of a Fully Automated 3D Hippocampal Segmentation Method Using Subjects with Alzheimer s Disease, Mild Cognitive Impairment, and Elderly Controls Jonathan H. Morra MS 1, Zhuowen Tu PhD 1, Liana
On cognitive performance as endpoint in clinical trials Ben Schmand
On cognitive performance as endpoint in clinical trials Ben Schmand Department of Neurology, Academic Medical Center Department of Psychology, University of Amsterdam The Netherlands What are the best
A Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing.
A Unique Partnership to Advance Alzheimer's Research through Whole Genome Sequencing. Dean Hartley, Ph.D., Alzheimer's Association, Emily Drabant, Ph.D., 23 and me, Anne Wojcicki, 23 and me, Rob Fetherstonhaugh,
NeuroImage 45 (2009) Contents lists available at ScienceDirect. NeuroImage. journal homepage:
NeuroImage 45 (2009) 645 655 Contents lists available at ScienceDirect NeuroImage journal homepage: www.elsevier.com/locate/ynimg Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study